West Pharmaceutical Services is a medical instruments & supplies business based in the US. West Pharmaceutical Services shares (WST) are listed on the NYSE and all prices are listed in US Dollars. West Pharmaceutical Services employs 10,600 staff and has a trailing 12-month revenue of around $2.9 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $277.16 |
|---|---|
| 52-week range | $309.90 - $415.03 |
| 50-day moving average | $329.16 |
| 200-day moving average | $354.92 |
| Wall St. target price | $399.63 |
| PE ratio | 41.9974 |
| Dividend yield | $0.78 (0.25%) |
| Earnings per share (TTM) | $7.57 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $277.16 from 2024-07-25
| 1 week (2024-07-19) | -12.82% |
|---|---|
| 1 month (2024-06-27) | -15.70% |
| 3 months (2024-04-26) | -23.10% |
| 6 months (2024-01-26) | -23.30% |
| 1 year (2023-07-27) | -21.90% |
|---|---|
| 2 years (2022-07-27) | -13.53% |
| 3 years (2021-07-27) | 378.38 |
| 5 years (2019-07-26) | 103.62% |
Valuing West Pharmaceutical Services stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of West Pharmaceutical Services's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
West Pharmaceutical Services's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 42x. In other words, West Pharmaceutical Services shares trade at around 42x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
West Pharmaceutical Services's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 6.7245. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into West Pharmaceutical Services's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
West Pharmaceutical Services's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $809.6 million.
The EBITDA is a measure of a West Pharmaceutical Services's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $2.9 billion |
|---|---|
| Operating margin TTM | 18.06% |
| Gross profit TTM | $1.1 billion |
| Return on assets TTM | 11.4% |
| Return on equity TTM | 20.84% |
| Profit margin | 19.42% |
| Book value | $36.72 |
| Market Capitalization | $23.3 billion |
TTM: trailing 12 months
Dividend payout ratio: 10.44% of net profits
Recently West Pharmaceutical Services has paid out, on average, around 10.44% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.25% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), West Pharmaceutical Services shareholders could enjoy a 0.25% return on their shares, in the form of dividend payments. In West Pharmaceutical Services's case, that would currently equate to about $0.78 per share.
While West Pharmaceutical Services's payout ratio might seem low, this can signify that West Pharmaceutical Services is investing more in its future growth.
West Pharmaceutical Services's most recent dividend payout was on 6 August 2024. The latest dividend was paid out to all shareholders who bought their shares by 30 July 2024 (the "ex-dividend date").
West Pharmaceutical Services's shares were split on a 2:1 basis on 26 September 2013. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your West Pharmaceutical Services shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for West Pharmaceutical Services shares which in turn could have impacted West Pharmaceutical Services's share price.
Over the last 12 months, West Pharmaceutical Services's shares have ranged in value from as little as $309.9009 up to $415.0347. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while West Pharmaceutical Services's is 0.995. This would suggest that West Pharmaceutical Services's shares are less volatile than average (for this exchange).
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.